Oppenheimer Upgrades Sarepta Therapeutics (SRPT) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts SRPT Hot Sheet
Price: $17.73 -2.48%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Oppenheimer analyst Hartaj Singh upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Perform to Outperform with a price target of $180.00.
For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.
Shares of Sarepta Therapeutics closed at $131.70 yesterday.
You May Also Be Interested In
- Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
- Freedom Broker Upgrades Procter & Gamble (PG) to Buy
- Aletheia Capital Upgrades KEI Industries Ltd (KEII:IN) to Long
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
